Patents by Inventor Stanley Richard Krystek, Jr.
Stanley Richard Krystek, Jr. has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11813315Abstract: The present invention relates to fibronectin-based scaffold domain proteins that bind to myostatin. The invention also relates to the use of these proteins in therapeutic applications to treat muscular dystrophy, cachexia, sarcopenia, osteoarthritis, osteoporosis, diabetes, obesity, COPD, chronic kidney disease, heart failure, myocardial infarction, and fibrosis. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the proteins.Type: GrantFiled: February 14, 2019Date of Patent: November 14, 2023Assignee: Bristol-Myers Squibb CompanyInventors: Sharon Cload, Linda Engle, Dasa Lipovsek, Malavi Madireddi, Ginger Chao Rakestraw, Joanna Swain, Wenjun Zhao, Hui Wei, Aaron P. Yamniuk, Vidhyashankar Ramamurthy, Alexander T. Kozhich, Martin J. Corbett, Stanley Richard Krystek, Jr.
-
Publication number: 20230312686Abstract: Provided herein are polypeptides which include tenth fibronectin type III domains (10Fn3) that bind to glypican-3. Also provided are fusion molecules comprising a 10Fn3 domain that bind to glypican-3 for use in diagnostic and therapeutic applications. Glypican-3 10Fn3 drug conjugates are also provided.Type: ApplicationFiled: November 10, 2022Publication date: October 5, 2023Inventors: Dasa LIPOVSEK, Joseph TOTH, Ginger C, RAKESTRAW, Irvith M. CARVAJAL, Stanley Richard KRYSTEK, JR., Steven R. O'NEIL, Guodong CHEN, Richard Y. HUANG, Bryan C. BARNHART, John Thomas LOFFREDO, III, Christina TERRAGNI
-
Patent number: 11524992Abstract: Provided herein are polypeptides which include tenth fibronectin type III domains (10Fn3) that bind to glypican-3. Also provided are fusion molecules comprising a 10Fn3 domain that bind to glypican-3 for use in diagnostic and therapeutic applications. Glypican-3 10Fn3 drug conjugates are also provided.Type: GrantFiled: January 24, 2020Date of Patent: December 13, 2022Assignee: Bristol-Myers Squibb CompanyInventors: Dasa Lipovsek, Joseph Toth, Ginger C. Rakestraw, Irvith M. Carvajal, Stanley Richard Krystek, Jr., Steven R. O'Neil, Guodong Chen, Richard Y. Huang, Bryan C. Barnhart, John Thomas Loffredo, Christina Terragni
-
Patent number: 11434275Abstract: Provided herein are polypeptides which include tenth fibronectin type III domains (10Fn3) that binds to serum albumin. Also provided are fusion molecules comprising a serum albumin binding 10Fn3 joined to a heterologous protein for use in diagnostic and therapeutic applications.Type: GrantFiled: January 21, 2020Date of Patent: September 6, 2022Assignee: BRISTOL-MYERS SQUIBB COMPANYInventors: Stanley Richard Krystek, Jr., Tracy S. Mitchell, Michael L. Gosselin, Dasa Lipovsek, Juhi Juneja
-
Publication number: 20220220220Abstract: The present invention provides novel antigen binding peptides, such as an antibody or antibody fragment, that specifically bind to selective FXIa inhibitors and/or dual inhibitors of FXIa, and plasma kallikrein. The present invention further relates to methods of reducing the antithrombotic effect of FXIa inhibitors by administering to a subject a pharmaceutically effective dose of the antigen binding peptides provided herein. In addition, the present invention provides detection reagents and methods for detecting the level of the inhibitors of FXIa in a biological sample.Type: ApplicationFiled: January 7, 2022Publication date: July 14, 2022Inventors: Joseph M. Luettgen, Lumelle Schneeweis, Ginger Chao Rakestraw, Christina Terragni, Andrew Karl Dilger, Jason Robert Pinckney, Steven Sheriff, Kevin Kish, Yongmi An, William R. Ewing, Stanley Richard Krystek, JR., Aaron Paul Yamniuk
-
Publication number: 20200283505Abstract: Provided herein are polypeptides which include tenth fibronectin type III domains (10Fn3) that binds to serum albumin. Also provided are fusion molecules comprising a serum albumin binding 10Fn3 joined to a heterologous protein for use in diagnostic and therapeutic applications.Type: ApplicationFiled: January 21, 2020Publication date: September 10, 2020Inventors: Stanley Richard KRYSTEK, JR., Tracy S. MITCHELL, Michael L. GOSSELIN, Dasa LIPOVSEK, Juhi JUNEJA
-
Patent number: 10766946Abstract: Provided herein are polypeptides which include tenth fibronectin type III domains (10Fn3) that binds to serum albumin. Also provided are fusion molecules comprising a serum albumin binding 10Fn3 joined to a heterologous protein for use in diagnostic and therapeutic applications.Type: GrantFiled: September 22, 2016Date of Patent: September 8, 2020Assignee: BRISTOL-MYERS SQUIBB COMPANYInventors: Stanley Richard Krystek, Jr., Tracy S. Mitchell, Michael L. Gosselin, Dasa Lipovsek, Juhi Juneja
-
Publication number: 20200262893Abstract: Provided herein are polypeptides which include tenth fibronectin type III domains (10Fn3) that bind to glypican-3. Also provided are fusion molecules comprising a 10Fn3 domain that bind to glypican-3 for use in diagnostic and therapeutic applications. Glypican-3 10Fn3 drug conjugates are also provided.Type: ApplicationFiled: January 24, 2020Publication date: August 20, 2020Inventors: Dasa LIPOVSEK, Joseph TOTH, Ginger C. RAKESTRAW, Irvith M. CARVAJAL, Stanley Richard KRYSTEK, Jr., Steven R. O'NEIL, Guodong CHEN, Richard Y. HUANG, Bryan C. BARNHART, John Thomas LOFFREDO, Christina TERRAGNI
-
Patent number: 10584160Abstract: Provided herein are polypeptides which include tenth fibronectin type III domains (10Fn3) that bind to glypican-3. Also provided are fusion molecules comprising a 10Fn3 domain that bind to glypican-3 for use in diagnostic and therapeutic applications. Glypican-3 10Fn3 drug conjugates are also provided.Type: GrantFiled: September 22, 2016Date of Patent: March 10, 2020Assignee: BRISTOL-MYERS SQUIBB COMPANYInventors: Dasa Lipovsek, Joseph Toth, Ginger C. Rakestraw, Irvith M. Carvajal, Stanley Richard Krystek, Jr., Steven R. O'Neil, Guodong Chen, Richard Y. Huang, Bryan C. Barnhart, John Thomas Loffredo, Christina Terragni
-
Publication number: 20190307855Abstract: The present invention relates to fibronectin-based scaffold domain proteins that bind to myostatin. The invention also relates to the use of these proteins in therapeutic applications to treat muscular dystrophy, cachexia, sarcopenia, osteoarthritis, osteoporosis, diabetes, obesity, COPD, chronic kidney disease, heart failure, myocardial infarction, and fibrosis. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the proteins.Type: ApplicationFiled: February 14, 2019Publication date: October 10, 2019Inventors: Sharon CLOAD, Linda ENGLE, Dasa LIPOVSEK, Malavi MADIREDDI, Ginger Chao RAKESTRAW, Joanna SWAIN, Wenjun ZHAO, Hui WEI, Aaron P. YAMNIUK, Vidhyashankar RAMAMURTHY, Alexander T. KOZHICH, Martin J. CORBETT, Stanley Richard KRYSTEK, JR.
-
Patent number: 10245302Abstract: The present invention relates to fibronectin-based scaffold domain proteins that bind to myostatin. The invention also relates to the use of these proteins in therapeutic applications to treat muscular dystrophy, cachexia, sarcopenia, osteoarthritis, osteoporosis, diabetes, obesity, COPD, chronic kidney disease, heart failure, myocardial infarction, and fibrosis. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the proteins.Type: GrantFiled: September 30, 2016Date of Patent: April 2, 2019Assignee: BRISTOL-MYERS SQUIBB COMPANYInventors: Sharon Cload, Linda Engle, Dasa Lipovsek, Malavi Madireddi, Ginger Chao Rakestraw, Joanna Swain, Wenjun Zhao, Hui Wei, Aaron P. Yamniuk, Vidhyashankar Ramamurthy, Alexander T. Kozhich, Martin J. Corbett, Stanley Richard Krystek, Jr.
-
Publication number: 20190077844Abstract: Provided herein are polypeptides which include tenth fibronectin type III domains (10Fn3) that bind to glypican-3. Also provided are fusion molecules comprising a 10Fn3 domain that bind to glypican-3 for use in diagnostic and therapeutic applications. Glypican-3 10Fn3 drug conjugates are also provided.Type: ApplicationFiled: September 22, 2016Publication date: March 14, 2019Inventors: Dasa LIPOVSEK, Joseph TOTH, Ginger C. RAKESTRAW, Irvith M. CARVAJAL, Stanley Richard KRYSTEK, JR., Steven R. O'NEIL, Guodong CHEN, Richard Y. HUANG, Bryan C. BARNHART, John Thomas LOFFREDO, Christina TERRAGNI
-
Publication number: 20180258158Abstract: Provided herein are polypeptides which include tenth fibronectin type III domains (10Fn3) that binds to serum albumin. Also provided are fusion molecules comprising a serum albumin binding 10Fn3 joined to a heterologous protein for use in diagnostic and therapeutic applications.Type: ApplicationFiled: September 22, 2016Publication date: September 13, 2018Applicant: BRISTOL-MYERS SQUIBB COMPANYInventors: Stanley Richard KRYSTEK, Jr., Tracy S. MITCHELL, Michael L. GOSSELIN, Dasa LIPOVSEK, Juhi JUNEJA
-
Publication number: 20170088602Abstract: The present invention relates to fibronectin-based scaffold domain proteins that bind to myostatin. The invention also relates to the use of these proteins in therapeutic applications to treat muscular dystrophy, cachexia, sarcopenia, osteoarthritis, osteoporosis, diabetes, obesity, COPD, chronic kidney disease, heart failure, myocardial infarction, and fibrosis. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the proteins.Type: ApplicationFiled: September 30, 2016Publication date: March 30, 2017Inventors: Sharon CLOAD, Linda ENGLE, Dasa LIPOVSEK, Malavi MADIREDDI, Ginger Chao RAKESTRAW, Joanna SWAIN, Wenjun ZHAO, Hui WEI, Aaron P. YAMNIUK, Vidhyashankar RAMAMURTHY, Alexander T. KOZHICH, Martin J. CORBETT, Stanley Richard KRYSTEK, JR.
-
Patent number: 9493546Abstract: The present invention relates to fibronectin-based scaffold domain proteins that bind to myostatin. The invention also relates to the use of these proteins in therapeutic applications to treat muscular dystrophy, cachexia, sarcopenia, osteoarthritis, osteoporosis, diabetes, obesity, COPD, chronic kidney disease, heart failure, myocardial infarction, and fibrosis. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the proteins.Type: GrantFiled: September 9, 2014Date of Patent: November 15, 2016Assignee: BRISTOL-MYERS SQUIBB COMPANYInventors: Sharon Cload, Linda Engle, Dasa Lipovsek, Malavi Madireddi, Ginger Chao Rakestraw, Joanna Swain, Wenjun Zhao, Hui Wei, Aaron P. Yamniuk, Vidhyashankar Ramamurthy, Alexander T. Kozhich, Martin J. Corbett, Stanley Richard Krystek, Jr.
-
Publication number: 20150072919Abstract: The present invention relates to fibronectin-based scaffold domain proteins that bind to myostatin. The invention also relates to the use of these proteins in therapeutic applications to treat muscular dystrophy, cachexia, sarcopenia, osteoarthritis, osteoporosis, diabetes, obesity, COPD, chronic kidney disease, heart failure, myocardial infarction, and fibrosis. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the proteins.Type: ApplicationFiled: September 9, 2014Publication date: March 12, 2015Inventors: Sharon CLOAD, Linda ENGLE, Dasa LIPOVSEK, Malavi MADIREDDI, Ginger Chao RAKESTRAW, Joanna SWAIN, Wenjun ZHAO, Hui WEI, Aaron P. YAMNIUK, Vidhyashankar RAMAMURTHY, Alexander T. KOZHICH, Martin J. CORBETT, Stanley Richard KRYSTEK, JR.
-
Patent number: 8853154Abstract: The present invention relates to fibronectin-based scaffold domain proteins that bind to myostatin. The invention also relates to the use of these proteins in therapeutic applications to treat muscular dystrophy, cachexia, sarcopenia, osteoarthritis, osteoporosis, diabetes, obesity, COPD, chronic kidney disease, heart failure, myocardial infarction, and fibrosis. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the proteins.Type: GrantFiled: September 12, 2013Date of Patent: October 7, 2014Assignee: Bristol-Myers Squibb CompanyInventors: Sharon Cload, Linda Engle, Dasa Lipovsek, Malavi Madireddi, Ginger Chao Rakestraw, Joanna Swain, Wenjun Zhao, Hui Wei, Aaron P. Yamniuk, Vidhyashankar Ramamurthy, Alexander T. Kozhich, Martin J. Corbett, Stanley Richard Krystek, Jr.